SCHEMBL834045

SCHEMBL834045

NC(Cc1cc(F)cc(F)c1)=NO

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.40
MAPK8 P45983 1/20 0.37
CYP2D6 P10635 1/20 0.35
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DBH P09172 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
CTBP2 P56545 1/20 0.32
EPHX1 P07099 1/20 0.32
MAPT P10636 1/20 0.32
NTRK1 P04629 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10264233 1.00 IDO1 (0.40) IDO1MAPK8CYP2D6LMNASMN1; SMN2
SCHEMBL100936 0.80 TAAR1 (0.50) IDO1MAPK8DBHTAAR1
SCHEMBL100935 0.80 TAAR1 (0.50) IDO1MAPK8DBHTAAR1
SCHEMBL103073 0.78 CTBP2 (0.53) IDO1MAPK8LMNASMN1; SMN2TAAR1
SCHEMBL103072 0.78 CTBP2 (0.53) IDO1MAPK8LMNASMN1; SMN2TAAR1
SCHEMBL12246356 0.77 LMNA (0.33) CYP2D6LMNASMN1; SMN2TAAR1MAPT
SCHEMBL837173 0.77 LMNA (0.33) CYP2D6LMNASMN1; SMN2TAAR1MAPT
SCHEMBL12246860 0.76 HTR3E (0.41) IDO1CYP2D6LMNASMN1; SMN2DBH
SCHEMBL836715 0.76 HTR3E (0.41) IDO1CYP2D6LMNASMN1; SMN2DBH
SCHEMBL9314494 0.76 ACHE (0.42) CYP2D6LMNASMN1; SMN2CTBP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272848-B1 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-12-26 EP disclosed
US-8143264-B2 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-03-27 US disclosed
US-8143264-B2 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-03-27 US disclosed
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GLAXOSMITHKLINE LLC 2011-10-20 US disclosed
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GLAXOSMITHKLINE LLC 2011-10-20 US disclosed
EP-2272848-A1 Xanthine derivatives as selective HM74A agonists Glaxosmithkline LLC (US) 2011-01-12 EP disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
US-20100168122-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2010-07-01 US disclosed
US-20100168122-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168122-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, XDH, GPR88 IDO1 1158/4885MAPK8 1593/4885CYP2D6 519/4885
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, GPR88, XDH IDO1 1063/4885MAPK8 1568/4885CYP2D6 886/4885
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS XDH, GPR84, GPR88 IDO1 1270/4885MAPK8 1488/4885CYP2D6 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.